GLP-1 Medications and Pregnancy: What You Need to Know

Medically reviewed by a licensed healthcare professional. Last updated March 2026.

The Critical Rule

GLP-1 medications must be stopped before becoming pregnant. This is not a gray area. Both semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) carry FDA pregnancy warnings, and no GLP-1 receptor agonist is approved for use during pregnancy.

Animal studies have shown potential harm to developing fetuses, including embryo-fetal death, structural abnormalities, and growth alterations at clinically relevant doses. While animal data does not always translate directly to humans, the findings are serious enough that the FDA classifies these medications with clear warnings against use during pregnancy.

If you are of childbearing age and taking a GLP-1 medication, planning ahead is essential.

Washout Periods: How Long Before Conception

Each GLP-1 medication has a different half-life, which determines how long the drug stays in your system after your last dose. Manufacturers recommend stopping the medication at least a specified period before planned conception to ensure the drug has been fully cleared.

Why the washout period is longer than the half-life: A drug is generally considered fully cleared after 5 half-lives. For semaglutide, that is approximately 5 weeks. The 2-month recommendation provides an additional safety margin. For tirzepatide, 5 half-lives is about 25 days, and the 1-month recommendation adds a buffer.

Your provider may recommend a longer washout depending on your specific situation, especially if you are on higher doses or have been on the medication for an extended period.

Birth Control Requirements

Because GLP-1 medications can potentially affect fetal development, reliable birth control is strongly recommended for women of childbearing potential throughout treatment. The prescribing information for both semaglutide and tirzepatide emphasizes this requirement.

An Important Interaction: Oral Contraceptives

GLP-1 medications slow gastric emptying, which can delay the absorption of oral medications, including birth control pills. This interaction is clinically relevant:

• Semaglutide may reduce the absorption rate (but not overall absorption) of oral contraceptives. The clinical significance is considered low, but some providers recommend additional precautions.
• Tirzepatide has a more studied interaction with oral contraceptives. The prescribing information specifically notes that oral contraceptive efficacy may be reduced, particularly during dose escalation.

Recommendations from prescribers:

• Consider using a non-oral form of birth control while on GLP-1 medications (IUD, implant, injection, patch, or ring)
• If you rely on oral contraceptives, discuss with your provider whether an additional barrier method is appropriate
• Be especially cautious during dose escalation periods, when the effect on gastric emptying is changing most rapidly

Planning Pregnancy

If you are considering becoming pregnant:

1. Talk to your prescriber about your timeline well in advance
2. Do not stop the medication abruptly on your own
3. Your provider will create a plan to taper or stop the medication while maintaining your health
4. Begin the washout period according to the timeline above
5. Continue reliable birth control until your provider confirms the washout is complete
6. Consider starting prenatal vitamins during the washout period

What If You Become Pregnant While on a GLP-1?

Unplanned pregnancies happen. If you discover you are pregnant while taking a GLP-1 medication:

• Stop the medication immediately and contact your prescriber the same day
• Do not panic. An unintentional exposure early in pregnancy does not automatically mean harm to the baby. The animal studies showing adverse effects used doses at or above the maximum human dose given throughout pregnancy.
• Your provider will assess the situation based on which medication you were taking, the dose, how far along you are, and the duration of exposure
• Additional monitoring such as more frequent ultrasounds may be recommended to track fetal development
• Report the exposure to the manufacturer's pregnancy registry if one exists. These registries help collect real-world safety data.

Novo Nordisk maintains a pregnancy exposure registry for semaglutide. Your provider can provide enrollment information. Contributing to this registry helps future patients by building the evidence base.

After Pregnancy: Resuming GLP-1 Medications

Breastfeeding

The safety of GLP-1 medications during breastfeeding has not been established. Here is what is known:

• Semaglutide: Animal studies show that semaglutide is present in breast milk. The effect on a breastfed infant is unknown. Novo Nordisk recommends considering either discontinuing breastfeeding or discontinuing semaglutide, weighing the benefit of breastfeeding and the mother's need for the medication.
• Tirzepatide: Tirzepatide has also been detected in the milk of lactating animals. Similar caution applies.

Most providers recommend against using GLP-1 medications while breastfeeding due to insufficient safety data. If you need to manage weight or diabetes postpartum, your provider will discuss alternative options that are better studied in breastfeeding women.

When You Can Restart

After pregnancy and once you have finished breastfeeding (if applicable), you can resume GLP-1 medications. Your provider will likely:

• Restart at the lowest dose and follow the standard escalation schedule
• Check your current metabolic status (weight, A1C, fasting glucose)
• Assess whether the medication is still the best choice for your postpartum health goals
• Consider timing relative to any plans for future pregnancies

Fertility Considerations

An important nuance that patients and providers should be aware of: significant weight loss can improve fertility, sometimes dramatically. This is especially true for women with PCOS (polycystic ovary syndrome) or obesity-related anovulation.

What this means practically:

• Women who were previously unable to conceive may become fertile after significant weight loss on GLP-1 medications
• This can lead to unplanned pregnancies if birth control is not being used
• If you have been told in the past that you are unlikely to conceive naturally, do not assume this is still true after losing 30 to 50+ pounds
• Discuss fertility changes with your provider as you lose weight

GLP-1s and Male Fertility

While the conversation about GLP-1 medications and reproduction primarily focuses on pregnancy, there are considerations for male patients as well:

• Animal studies with semaglutide showed effects on male fertility parameters at high doses, though these doses exceeded the maximum human dose
• Limited human data is available, but no significant adverse effects on sperm parameters have been reported at standard doses
• If you are a man planning to conceive with your partner, discuss your GLP-1 medication with your provider

Key Takeaways

• Stop GLP-1 medications at least 2 months before planned conception (semaglutide) or 1 month (tirzepatide)
• Use reliable, preferably non-oral, birth control throughout treatment
• Weight loss can improve fertility unexpectedly, so do not skip birth control
• If you become pregnant while on a GLP-1, stop immediately and contact your provider
• Most providers advise against breastfeeding while on GLP-1 medications
• Plan ahead and involve your prescriber early in your pregnancy planning

---

Ready to start your weight loss journey? Find a GLP-1 clinic near you and connect with a qualified provider today.

---

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you are experiencing a medical emergency, call 911.